-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Initiates Coverage On Theravance Biopharma with Outperform Rating, Announces Price Target of $27

Benzinga·12/03/2025 16:31:12
语音播报
Oppenheimer analyst Trevor Allred initiates coverage on Theravance Biopharma (NASDAQ:TBPH) with a Outperform rating and announces Price Target of $27.